ZLAB - Zai Lab Limited
Zai Lab Limited
Jinchuang Plaza
Building 1, Fourth Floor 4560 Jinke Road Pudong
Shanghai 201210
China
86 21 6163 2588
https://www.zailaboratory.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 2,036
Key executives
| Name | Title | Pay | Exercised | Year born |
|---|---|---|---|---|
| Dr. Ying Du Ph.D. | Founder, Chairperson & CEO | 1.67M | N/A | 1966 |
| Mr. Joshua L. Smiley | Pres & COO | 647.11k | N/A | 1970 |
| Dr. Rafael G. Amado M.D. | Pres and Head of Global Oncology R&D | 477k | N/A | 1964 |
| Mr. Ki Chul Cho | Chief Financial Officer | 748.24k | N/A | 1978 |
| Dr. Harald Reinhart M.D. | Pres and Head of Global Devel. for Neuroscience, Autoimmune & Infectious Diseases | 923.33k | 68.6k | 1952 |
| Dr. Peter Huang Ph.D. | Chief Scientific Officer | N/A | N/A | N/A |
| Mr. Frazor Titus Edmondson III | Chief Legal Officer & Corp. Sec. | N/A | N/A | 1966 |
| Ms. Ann E. Beasley J.D. | Chief Compliance Officer | N/A | N/A | N/A |
| Dr. Ning Xu M.D. | Exec. VP & Head of Clinical Operations | N/A | N/A | 1965 |
| Dr. Jonathan J. Wang MBA, Ph.D. | Chief Bus. Officer | N/A | N/A | 1982 |
Description
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. Its commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. The company also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, it develops Zipalertinib for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; ZL-2313, an investigational oral EGFR inhibitor; ZL-1211, a humanized IgG1 monoclonal antibody that targets CLDN18.2; ZL-1218 is humanized IgG1 monoclonal antibody to induce potent antibody-dependent cellular cytotoxicity activity that enables NK cell-mediated killing of CCR8-expressing T-regs; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter; and KarXT for the treatment of psychiatric and neurological conditions. The company was incorporated in 2013 and is headquartered in Shanghai, China.
Corporate governance
Zai Lab Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.
